| Popis: |
To explore the therapeutic regimens of metastatic prostate cancer so as to provide the experimental rationales for its gene therapy.The adenoviral vectors expressing cytokines interleukin-18 (IL-18) and interleukin-12 (IL-12) were used to induce tumor regression in a C57BL/6 murine model of prostate cancer (n = 110).Adenoviral vectors could express IL-18 and IL-12 effectively. The rates of tumorigenesis were 10/10, 10/10, 4/10, 5/10 and 2/10, the durations of tumor growth (12.3 ± 1.5), (12.8 ± 1.0), (15.4 ± 1.3), (14.8 ± 0.8), (24.5 ± 2.2) days and the diameters of tumor nodule after inoculation 30 days (37.0 ± 3.0), (35.0 ± 4.6), (25.0 ± 2.0), (27.0 ± 4.1) and (9.5 ± 3.2) mm respectively in inoculation wild-type, AdLacZ, AdmIL-18, AdhIL-12, AdmIL-18 and AdhIL-12 of RM-1 cell. Compared to the other four groups, AdmIL-18 and AdhIL-12 developed smaller and delayed tumors (P0.01). Intratumoral injection of Adm IL-18 and AdhIL-12 could not only regress the established tumors, but also reduce the number of distal lung metastases (P0.01).Adenovirus-mediated delivery of IL-18 and IL-12 locally by intratumoral injection is highly effective in inducing specific antitumor immune responses. |
